Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrate-resistant prostate cancer (CRPC).

被引：21
|
作者：
Park, Jong Chul
Sartor, A. Oliver
Sullivan, Rana
King, Serina
Antonarakis, Emmanuel S.
机构：
[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[2] Tulane Canc Ctr, New Orleans, LA USA
[3] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Marriottsville, MD USA
[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps5076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5076
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC)
    Marshall, Catherine Handy
    Park, Jong Chul
    DeWeese, Theodore L.
    King, Serina
    Afful, Michaella
    Hurrelbrink, Julia
    Manogue, Charlotte
    Cotogno, Patrick
    Moldawer, Nancy P.
    Barata, Pedro C.
    Drake, Charles G.
    Posadas, Edwin M.
    Armstrong, Andrew J.
    Sartor, A. Oliver
    Antonarakis, Emmanuel S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer
    Marshall, Catherine H.
    Fu, Wei
    Wang, Hao
    Park, Jong Chul
    DeWeese, Theodore L.
    Tran, Phuoc T.
    Song, Daniel Y.
    King, Serina
    Afful, Michaella
    Hurrelbrink, Julia
    Manogue, Charlotte
    Cotogno, Patrick
    Moldawer, Nancy P.
    Barata, Pedro C.
    Drake, Charles G.
    Posadas, Edwin M.
    Armstrong, Andrew J.
    Sartor, Oliver
    Antonarakis, Emmanuel S.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (06) : 1623 - 1630
  • [3] Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer
    Gardner, Thomas A.
    Elzey, Bennett D.
    Hahn, Noah M.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (04) : 534 - 539
  • [4] Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer.
    Marshall, Catherine Handy
    Park, Jong Chul
    Fu, Wei
    Wang, Hao
    DeWeese, Theodore L.
    King, Serina
    Afful, Michaella
    Hurrelbrink, Julia
    Manogue, Charlotte
    Cotogno, Patrick
    Moldawer, Nancy P.
    Barata, Pedro C.
    Drake, Charles G.
    Posadas, Edwin Melencio
    Armstrong, Andrew J.
    Sartor, A. Oliver
    Antonarakis, Emmanuel S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] A phase II randomized, open label study of sipuleucel-T versus sipuleucel-T and tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC)
    Pill, Roberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
    Sims, Robert B.
    [J]. JOURNAL OF CANCER, 2011, 2 : 357 - 359
  • [7] Pain Response to Radium-223 in Men With Metastatic Castrate-Resistant Prostate Cancer
    Zhang, I.
    Gilbo, P.
    Cox, B. W.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E530 - E530
  • [8] Clinical response to radium-223 dichloride in men with metastatic castrate-resistant prostate cancer
    Zhang, Isabella
    Gilbo, Philip
    Kohn, Nina
    Cox, Brett
    [J]. PRACTICAL RADIATION ONCOLOGY, 2018, 8 (06) : 452 - 457
  • [9] Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
    Quinn, Zachary
    Leiby, Benjamin
    Sonpavde, Guru
    Choudhury, Atish D.
    Sweeney, Christopher
    Einstein, David
    Szmulewitz, Russell
    Sartor, Oliver
    Knudsen, Karen
    Yang, Eddy Shih-Hsin
    Kelly, Wm. Kevin
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (01) : 50 - 59
  • [10] OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
    Corman, J.
    Dawson, N.
    Hall, S.
    Nabhan, C.
    Ferrari, A.
    Armstrong, A. J.
    Murdock, M. I.
    Stewart, F.
    Sheikh, N.
    Petrylak, D. P.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 311 - 311
12345